 New subgroup analysis of the Phase 3 PRIME study reveals improvement in efficacy outcomes for ZEJULA niraparib maintenance treatment when started within 12 weeks after first-line platinum-based chemotherapy 1LCT New subgroup analysis of the Phase 3 PRIME study reveals improvement in efficacy outcomes for ZEJULA niraparib maintenance treatment when started within 12 weeks after first-line platinum-based chemotherapy 1LCT 